1 services found
Atriva Therapeutics GmbH Services
-
Research & Development Services
The company’s lead drug candidate is the MEK inhibitor zapnometinib. The small molecule, which can be administered orally (tablet), is under advanced clinical development in two severe respiratory viral diseases: COVID-19 and influenza, two disease areas with urgent need for effective ...